Latest Competition News

Forte Energy has rapidly expanded its oil and gas exploration portfolio in Alaska’s National Petroleum Reserve, acquiring over 156,000 acres including the billion-barrel Harrier Prospect and adjacent leases to Umiat Oil Field, while securing significant cost savings through lease fee suspensions.

Gibb River Diamonds (ASX:GIB) has completed mining and processing at its Neta JV within the Edjudina Gold Project, generating over 5,200 ounces of gold and receiving a $7 million profit share. The company is progressing exploration on a new lease near Neta and maintains a strong cash position to support further growth.

Aureka Limited extends its Victorian gold resource ambitions with strong drilling results at Irvine and Comstock, backed by fresh geophysical data and secured tenure.

Latrobe Magnesium has achieved continuous production of high-grade Magnesium Oxide from brown coal ash and secured a US$2 million prepayment from its US offtake partner, setting the stage for magnesium metal production in the second half of 2026.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

Beonic Limited’s Q3 FY26 results highlight a tripling of EBITDA margin to 15.8%, driven by operational leverage and gross margin expansion, while the Moroccan Airports rollout stays on track for full delivery by June 2026.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Bellavista Resources has secured an 80% stake in the high-grade Pickle Crow Gold Project in Ontario, backed by a two-tranche A$35 million placement. The company also advanced bioleaching research at its Brumby Project, signalling diversified exploration progress.

OpenLearning accelerated its SaaS annual recurring revenue by 35% year-on-year to $3.192 million in Q1 FY26, propelled by larger multi-year LMS contracts and ongoing AI platform enhancements.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

BSA Limited recorded a break-even Q3 FY2026 as revenue and EBITDA fell sharply year-to-date due to lost contracts, but the company maintains a solid cash buffer to fund its transition.